These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

715 related items for PubMed ID: 22227456

  • 1. Application of albumin prior to delayed thrombolysis reduces brain edema and blood brain barrier permeability in an embolic stroke model.
    Lu HT, Zhao JG, Li MH, Li YD.
    Brain Res; 2012 Feb 15; 1438():75-84. PubMed ID: 22227456
    [Abstract] [Full Text] [Related]

  • 2. Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.
    Zhang L, Zhang ZG, Liu X, Hozeska A, Stagliano N, Riordan W, Lu M, Chopp M.
    Thromb Haemost; 2006 Jan 15; 95(1):166-73. PubMed ID: 16543976
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy of moderate hypothermia and thrombolysis in experimental thromboembolic stroke--an MRI study.
    Kollmar R, Henninger N, Bardutzky J, Schellinger PD, Schäbitz WR, Schwab S.
    Exp Neurol; 2004 Nov 15; 190(1):204-12. PubMed ID: 15473993
    [Abstract] [Full Text] [Related]

  • 4. Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.
    Zarisfi M, Allahtavakoli F, Hassanipour M, Khaksari M, Rezazadeh H, Allahtavakoli M, Taghavi MM.
    Brain Res Bull; 2017 Sep 15; 134():85-90. PubMed ID: 28710023
    [Abstract] [Full Text] [Related]

  • 5. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat.
    Zhang L, Zhang ZG, Ding GL, Jiang Q, Liu X, Meng H, Hozeska A, Zhang C, Li L, Morris D, Zhang RL, Lu M, Chopp M.
    Circulation; 2005 Nov 29; 112(22):3486-94. PubMed ID: 16316970
    [Abstract] [Full Text] [Related]

  • 6. Diffusion-, T2-, and perfusion-weighted nuclear magnetic resonance imaging of middle cerebral artery embolic stroke and recombinant tissue plasminogen activator intervention in the rat.
    Jiang Q, Zhang RL, Zhang ZG, Ewing JR, Divine GW, Chopp M.
    J Cereb Blood Flow Metab; 1998 Jul 29; 18(7):758-67. PubMed ID: 9663506
    [Abstract] [Full Text] [Related]

  • 7. [Does the result of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in rabbits depend on the erythrocyte- and fibrin-content of a thrombus?].
    Kirchhof K, Sikinger M, Welzel T, Zoubaa S, Sartor K.
    Rofo; 2004 Jan 29; 176(1):98-105. PubMed ID: 14712413
    [Abstract] [Full Text] [Related]

  • 8. Ascorbic Acid Reduces the Adverse Effects of Delayed Administration of Tissue Plasminogen Activator in a Rat Stroke Model.
    Allahtavakoli M, Amin F, Esmaeeli-Nadimi A, Shamsizadeh A, Kazemi-Arababadi M, Kennedy D.
    Basic Clin Pharmacol Toxicol; 2015 Nov 29; 117(5):335-9. PubMed ID: 25899606
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cerebroprotective effects of TAK-937, a novel cannabinoid receptor agonist, in permanent and thrombotic focal cerebral ischemia in rats: therapeutic time window, combination with t-PA and efficacy in aged rats.
    Murakami K, Suzuki M, Suzuki N, Hamajo K, Tsukamoto T, Shimojo M.
    Brain Res; 2013 Aug 14; 1526():84-93. PubMed ID: 23791950
    [Abstract] [Full Text] [Related]

  • 12. Epigallocatechin Gallate Extends the Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment in Ischemic Rats.
    You YP.
    J Stroke Cerebrovasc Dis; 2016 Apr 14; 25(4):990-7. PubMed ID: 26851971
    [Abstract] [Full Text] [Related]

  • 13. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke.
    Romanos E, Planas AM, Amaro S, Chamorro A.
    J Cereb Blood Flow Metab; 2007 Jan 14; 27(1):14-20. PubMed ID: 16596120
    [Abstract] [Full Text] [Related]

  • 14. Cerebralcare Granule® attenuates blood-brain barrier disruption after middle cerebral artery occlusion in rats.
    Huang P, Zhou CM, Qin-Hu, Liu YY, Hu BH, Chang X, Zhao XR, Xu XS, Li Q, Wei XH, Mao XW, Wang CS, Fan JY, Han JY.
    Exp Neurol; 2012 Oct 14; 237(2):453-63. PubMed ID: 22868201
    [Abstract] [Full Text] [Related]

  • 15. FK-506 extended the therapeutic time window for thrombolysis without increasing the risk of hemorrhagic transformation in an embolic rat stroke model.
    Okubo S, Igarashi H, Kanamatsu T, Hasegawa D, Orima H, Katayama Y.
    Brain Res; 2007 Apr 27; 1143():221-7. PubMed ID: 17316578
    [Abstract] [Full Text] [Related]

  • 16. Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.
    El Amki M, Lerouet D, Coqueran B, Curis E, Orset C, Vivien D, Plotkine M, Marchand-Leroux C, Margaill I.
    Exp Neurol; 2012 Dec 27; 238(2):138-44. PubMed ID: 22921458
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
    Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P, Coleman TA, Lawrence DA, Chopp M.
    Circulation; 2002 Aug 06; 106(6):740-5. PubMed ID: 12163437
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of tissue plasminogen activator timing on blood-brain barrier permeability and hemorrhagic transformation in rats with transient ischemic stroke.
    Zhang Y, Wang Y, Zuo Z, Wang Z, Roy J, Hou Q, Tong E, Hoffmann A, Sperberg E, Bredno J, Berr SS, Xie M, Lee K, Wintermark M.
    J Neurol Sci; 2014 Dec 15; 347(1-2):148-54. PubMed ID: 25292413
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.